Now Approved CAMZYOS™ (mavacamten) capsules logo
Now Approved CAMZYOS™ (mavacamten) capsules logo
Indication
CAMZYOS is indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II–III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms.

Redefining the Treatment Landscape for Symptomatic
NYHA Class II–III Obstructive HCM1,2

CAMZYOS is the first and only approved cardiac myosin inhibitor that targets HCM at the source.1,2
CAMZYOS is a once-daily oral medication with individualized dosing and administration1
See recommended dosing and administration, including titration and monitoring information

This website is best viewed
using the horizontal display
on your tablet device.

This website is best viewed
using the vertical display
on your mobile device.

References:

  1. CAMZYOS [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2022.
  2. Olivotto I, Oreziak A, Barriales-Villa R, et al; EXPLORER-HCM study investigators. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet.
    2020;396(10253):759-769.